Teva CEO Sees Strong Austedo Demand Cushioning Medicare Pricing Blow in 2027

What happened

Teva CEO sees demand for Austedo cushioning a Medicare pricing impact in 2027. In the supplied article, Teva reported adjusted third-quarter earnings of 86 cents per share and revenue of $4.395 billion, while revenue fell 2% year over year. Its three key branded drugs generated about $1.1 billion, up 33% year over year in local currency.

Confirmed

Global impact / market context

The reported growth in Austedo, Ajovy and Uzedy provides a revenue offset to falling generic-drug sales, especially lenalidomide. If Austedo demand remains strong as Medicare pricing changes take effect in 2027, it could cushion pressure on Teva’s sales, though the article gives no expected size for that impact.

Analyst inference

Teva’s results show a split between growing branded-drug revenue and declining generics revenue: the three named brands rose 33%, while global generics revenue fell 16% in local currency. That mix matters because continued generic weakness could limit overall revenue even as branded products expand.

Confirmed

What to watch

1. Watch whether Austedo demand continues to support sales as the stated Medicare pricing impact approaches in 2027; the article provides no forecast of the size of either effect. Analyst inference
2. Track future sales of lenalidomide and other generics: the article says lower U.S. lenalidomide sales weighed on revenue, while new launches and biosimilar growth partly offset declines. Analyst inference
3. Compare future growth in Austedo, Ajovy and Uzedy with generic-drug performance to see whether branded sales can keep offsetting weakness in Teva’s generics business. Analyst inference

Evidence

• Original source link unavailable